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ROS Signalingminutes) ischemia/reperfusion cycles (ischemic preconditioning, IP) limits
myocardial injury produced by a subsequent prolonged period of coronary artery occlusion and
reperfusion. Postconditioning (PostC), which is a series of brief (a few seconds) reperfusion/ischemia
cycles at reperfusion onset, attenuates also ischemia/reperfusion injury. In recent years the main idea has
been that reactive oxygen species (ROS) play an essential, though double-edged, role in cardioprotection:
they may participate in reperfusion injury or may play a role as signaling elements of protection in the pre-
ischemic phase. It has been demonstrated that preconditioning triggering is redox-sensitive, using either
ROS scavengers or ROS generators. We have shown that nitroxyl triggers preconditioning via pro-oxidative,
and/or nitrosative stress-related mechanism(s). Several metabolites, including acetylcholine, bradykinin,
opioids and phenylephrine, trigger preconditioning-like protection via a mitochondrial KATP-ROS-
dependent mechanism. Intriguingly, and contradictory to the above mentioned theory of ROS as an
obligatory part of reperfusion-induced damage, some studies suggest the possibility that some ROS at low
concentrations could protect ischemic hearts against reperfusion injury. Yet, we demonstrated that
ischemic PostC is also a cardioprotective phenomenon that requires the intervention of redox signaling to
be protective. Emerging evidence suggests that in a preconditioning scenario a redox signal is required
during the ﬁrst few minutes of myocardial reperfusion following the index ischemic period. Intriguingly,
the ROS signaling in the early reperfusion appear crucial to both preconditioning- and postconditioning-
induced protection. Therefore, our and others' results suggest that the role of ROS in reperfusion may be
reconsidered as they are not only deleterious.
© 2009 Elsevier B.V. All rights reserved.1. AimThis review is focused on acute injury and cardioprotection. Acute
cardiac ischemia/reperfusion injury is due to cardiac dysfunction and
cell death (apoptosis, autophagy and necrosis), but does not include
the inﬂammatory response, which follows necrosis. Acute cardiopro-
tection is mainly mediated by activation of signaling pathways and
post-translational modiﬁcation of proteins. In particular, this review
focuses on two well-deﬁned mechanisms of cardioprotection, namely
preconditioning and postconditioning. We ﬁrst examine how free
radicals promote cardiac injury and how, paradoxically, they can also
protect myocardium against ischemia/reperfusion injury in precon-
ditioning and postconditioning scenarios. With respect to redox-
mechanisms in preconditioning we consider the so-called early phase
or ﬁrst window of protection only.iche e Biologiche Università di
. Tel.: +39 11 6705430/5450;
ro).
ll rights reserved.The mechanisms involved in the so-called second window or
delayed protection will be only mentioned. Since they are mainly
mediated by gene induction and de-novo protein synthesis, the reader
is referred to other extensive reviews [1–12].
2. Deﬁnition of free radicals
Free radicals are molecules and atoms with unpaired electrons in
their outer shell. They are highly reactive and are formed in processes
that involve oxygen. Free radicals that originate from oxygen are
called reactive oxygen species (ROS), whereas free radicals that
originate from the reaction of oxygen with nitrogen are considered a
subclass of free radicals and are called reactive nitrogen species
(RNS). Oxygen free radicals include superoxide anion (O2−) and
hydroxyl radical (OH·), while RNS include nitric oxide (NO·)
and peroxynitrite (ONOO−), the latter being originated by a reaction
of O2− with NO·. RNS also include nitrogen dioxide (NO2·) and
nitrosyl hydride (HNO) [13]. Such RNS may have biologic activities
distinct from those of the parent molecules [e.g. [14–38]. In
particular, in a biological system where O2 or superoxide are present,
NO· may be considered a reactive radical, when involved in the so-
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reactions occurring between NO· and speciﬁc biological molecules.
[39]. Accordingly, NO· may act as an important oxidative biological
signaling molecule in a large variety of diverse physiological
processes including cardioprotection, smooth muscle relaxation,
blood pressure regulation, neurotransmission, defense mechanisms,
immune regulation, and platelet function [36–38].
Hydrogen peroxide (H2O2), which is not a free radical, is often
discussed with ROS because it is very reactive. It can be formed from
superoxide anion and can generate hydroxyl radicals. In fact, strong
oxidants are produced through Fenton-type reactions of H2O2 with
transition metal complexes [for reviews see [14–24].
3. Sources of ROS and RNS
Several enzymes and biochemical processes can produce ROS and
RNS. The major sources of oxidative stress in cardiovascular system
are the following: (a) the enzymes xanthine oxidoreductase, (b) NAD
(P)H oxidase (multisubunit membrane complexes), (c) nitric oxide
synthases (NOSs) and (d) the mitochondrial cytochromes [14–27].
Actually, in the myocardium the main source of ROS is located in
mitochondria. It seems that these organelles can produce a low
amount of ROS from respiratory complex and can produce a large
quantity of ROS from Monoamine Oxidase (MAO) and p66Shc [28].
Even NOSs can produce O2− and OH·, instead of NO· under certain
conditions, as in the absence of tetrahydrobiopterin (BH4). Yet, it has
been proposed that when NO· is produced, HNO is the primary
product, which subsequently is transformed to NO· in the presence of
superoxide dismutase (SOD) [9,19,20,24,29–33]. Usually, NO· is
generated in biological tissues by speciﬁc NOSs (constitutive and
inducible forms), which metabolize L-arginine to citrulline with the
formation of NO· via a ﬁve electron oxidative reaction
[1,2,9,10,14,16,18–24,31–36]. Mitochondria also contain a constitutive
isoform of NOS [17,26,36].
Hemoglobin can also be considered a source of free radicals. In
particular NOSs and hemoglobin are the principal sources of RNS,
including NO· and NO· modiﬁed cysteine thiols (SNOs) in amino
acids, peptides, and proteins. SNOs together with other biological
reactions they convey NO· bioactivity in processes that are
collectively known as non-enzymatic sources of NO· [12,39,40].
It has been suggested that triggering ROS alone is not sufﬁcient
for massive ROS release from mitochondria, but that the involve-
ment of the mitochondrial permeability transition pore (mPTP) may
be required. Zorov et al. [41], working with isolated adult rat
cardiomyocytes, “triggered” ROS release via intracellular photoacti-
vation of tetramethylrhodamine compounds. These triggered ROS
were associated with mitochondrial depolarization along with mPTP
induction and a consequent large burst of ROS from mitochondria.
Thus a positive feedback loop of “ROS-induced ROS release” has
been suggested [41].
3.1. Defense mechanisms
Biological systems have several defense mechanisms against ROS,
which in some circumstances can be overcome and in others may be
strengthened by therapies and protective maneuvers. These mechan-
isms may be enzymatic or non-enzymatic in nature. Enzymes
include catalase, glutathione peroxidase, thioredoxin reductase and
superoxide dismutase, while non-enzymatic antioxidants include
coenzyme Q, thioredoxins, some vitamins and minerals, as well as
omega 3 fatty acids [14,19,20,23,42]. Nitric oxide can also be
considered an antioxidant under certain conditions [14,19,20,23].
For instance, NO· protects against exogenously applied ONOO− via
secondary reactions [14,16,23,31,43]. Actually most ischemia/reper-
fusion studies found a depletion of myocardial non-enzymatic
antioxidants (including NO·) with either a decrease, an increase orno change in activities of myocardial enzymatic antioxidants
[44–55]. Antioxidants may also play a role as triggers of signaling
cascade [54]. The emerging picture is that cells are protected against
ischemia/reperfusion injury when they maintain a delicate balance
between the protective oxidant/antioxidant signaling versus detri-
mental effects for reviews see [44,54,55].
Traditionally free radicals have been considered useless by-
products of metabolism, deleterious to biological systems. It is now
clear that low concentrations of some ROS and RNS play a pivotal role
in signaling cascades that are essential for many biological responses
including cardioprotection (see below). First let's consider the
generation of free radicals in ischemia/reperfusion, then their
deleterious role, and ﬁnally their beneﬁcial/signaling effects.
4. Role of free radicals in ischemia and reperfusion
4.1. Generation of free radicals during ischemia
It is likely that the generation of ROS in hearts during ischemia is
occurring. Even in a global model of ischemia tissue oxygen
concentration does not immediately fall to zero, therefore an initial
generation of ROS is possible. In fact, production of ROS during
ischemia has been observed in isolated cardiomyocytes and isolated
hearts [44–46]. However, caution must be used in drawing
conclusions since radicals can be generated in these models by the
oxygen present in the ambient/solution and not present in intact
ischemic myocardium. Nevertheless, the levels of ROS generated
during ischemia are generally low, and their pathological signiﬁ-
cance is uncertain. Yet, the amount and type of ROS may be
heterogeneous depending on the level of antioxidants and residual
tissue oxygenation, which will depend on factors such as collateral
ﬂow and pre-ischemic treatments. It has been proposed that these
ischemia-generated ROS may play an important signaling role [47]
and that they could be the actual ROS that is triggering precondi-
tioning [48] (see below).
4.2. Generation of free radicals during reperfusion
Reactive oxygen species are known to be produced in large
quantities in the ﬁrst fewminutes of post-ischemic reperfusion aswell
as under inﬂammatory conditions. Since ROS and RNS can interact,
several alternative outcomes are possible [e.g. 14–24].
It is generally accepted that steadily high concentrations of free
radicals contribute to the pathogenesis of several diseases, especially
when normal defense mechanisms are impaired. These are usually
age-related, multi-causal diseases such as malignancy, infections,
diabetes, arteriosclerosis, etc. Thus free radicals may contribute to
initiation, manifestation and complications of speciﬁc diseases.
In 1973, Hearse et al. published a paper [49] in which they
demonstrated that after anoxia, reoxygenation of isolated rat hearts
resulted in a massive release of cardiac enzymes and cell death.
Following Hearse's paper the term “oxygen paradox” was introduced
and caused an explosion of studies investigating the effects of ROS on
the heart.
4.3. Mechanisms of reperfusion-induced cell death
These mechanisms are not completely understood, but it is likely
that the occurrence of oxidative stress related to the generation of free
radicals might play an important role [5,8–10,12,28,44,50–52].
When the occlusion of the coronary branch that perfuses the
ischemic myocardium is removed, the superoxide anion (O2−)
production increases as a result of the activation of various enzymatic
complexes. The superoxide anion and other ROS strongly oxidize the
myocardial ﬁbers already damaged by the ischemia, thus favoring the
apoptosis [49–61]. In reperfusion, O2− reacts with the nitric oxide,
Fig. 1. Schematic representation of ischemic preconditioning protocol. Ischemic
preconditioning (IP) limits the severity of the ischemia/reperfusion injury. Infarct
area is reduced by 30–80% versus matched controls with matched risk areas. IP also
reduces ischemia/reperfusion arrhythmias and may reduce post-ischemic contractile
dysfunction.
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sign of a reduced availability of NO· [62,63] and it may participate
with O2− to the lesion of myocardium [62–68]. In particular, high
ONOO− concentrations are considered to be highly cytotoxic [66–68].
The contribution of peroxynitrite generation to myocardial and
vascular dysfunction during ischemia and reperfusion, myocarditis,
chronic heart failure, and various other cardiovascular pathologies has
recently been reviewed [64,65,68]. Superoxide anion dependent
damages are reduced if O2− is transformed into hydrogen peroxide
(H2O2) by the superoxide dismutase. However, since in the presence
of Fe2+ or Cu2+, the H2O2 can be transformed into hydroxyl radical
(OH·) and hydroxyl anion (HO−), which aremore toxic than O2− and
H2O2, an increase in toxicity can occur. In addition ONOO− cytotoxicity
can occur, which can be reduced by the addition of NO· via a
secondary reaction [16,19,20,43].
The oxidative injury due to increased free radical formation leads
to changes in membrane permeability, membrane lipid bilayer
disruption and functional modiﬁcation of various cellular proteins.
In fact, oxidative stress is associated with modiﬁcations of membrane
phospholipids and proteins leading to peroxidation and oxidation of
thiol groups [9,14,15,19,20,30,32,69,70]. In addition to cellular protein
and lipid damage, alterations in myocyte function due to increased
oxidative stress are associated with the effects of free radicals on
subcellular organelles. For instance, it has been suggested that oxygen
free radicals may inﬂuence Ca2+ movements in the cell by depressing
the activity of both the sarcolemmal ATP-independent Ca2+-binding
and the activity of the ecto-ATPase. Yet, sarcolemma incubated for
1 min with superoxide results in 15% reduction in the sarcolemmal
ATP-dependent Ca2+ accumulation and Ca2+-stimulated ATPase
activities. These effects may be oxygen-radical species speciﬁc
[71,72]. Therefore, myocardial damages during ischemia/reperfusion
can be due to a “vicious circle” with a massive quantity of ROS
inducing the cellular and mitochondrial overload of Ca2+, with
consequent release of a massive quantity of ROS. Ultimately, these
may contribute to the activation of mPTP, to the reduced availability of
NO· and to the activation of the transcription factor NFκB (For the role
of NFκB see reviews [e.g. 1–12]).
The mPTP opening may represent the moment of “no return” for
cell death. Although, mPTP opening might be caused by ischemia in
the absence of reperfusion [73], the conditions associated with
reperfusion, such as massive ROS accumulation, pH normalization
and [Ca2+] rise, create an ideal scenario for mPTP opening [3–7,74–
76]. NO· deﬁciency can also cause vasoconstriction and formation of
micro-thrombi into the lumen of the small vessels [38,43,50,77,78].
These mechanisms, combined with the adhesion of the leucocytes to
the endothelium, induced by ROS, can lead to the so-called “no-reﬂow
phenomenon” [43,50,78]. As a consequence, free radicals have also
downstream effects, resulting in the initiation and progression of a
highly orchestrated acute inﬂammatory response through the release
of cytokines, activation of vascular endothelial cells and leukocytes
with expression of cell surface adhesion molecules, and up-regulation
of a program of pro-inﬂammatory genes, which contribute to the
onset and maintenance of post-ischemic inﬂammation [78–81].
Since cardiac oxidative injury, initiated by ischemia, occurs mainly
during reperfusion, the relative proportion of injury occurring during
ischemia versus reperfusion is likely to depend on the duration of
ischemia. As we will see, this fact make cardiac protection in
reperfusion possible.
In 1996, a study on the angiotensin II mediated vasoconstriction
[82], demonstrated that ROS are not just general toxins, but they also
act as second messengers in discrete signal transduction pathways.
Then, the signaling role of ROS (as opposed to excess ROS in the
development of injury) started to emerge. Nevertheless, free radicals
are still considered by many physicians as dangerous/useless by-
products of metabolism that should be eliminated whenever possible.
However, scavengers of free radicals were not effective in making theheart resistant to cell death in ischemia/reperfusion [80,83–86]. In
fact, not all redox conditions are detrimental to the heart. In recent
years the importance of ROS signaling has been examined closely in
great detail [i.e. [9,10,12,38,87–89].
5. Preconditioning
In 1986, ischemic preconditioning (IP) was ﬁrst described by
Murry et al. [90]. It consists of brief periods (a few minutes) of
ischemia, separated from one another by brief periods (a few
minutes) of reperfusion just prior to a sustained period of ischemia
followed by reperfusion (see Fig. 1). Preconditioning limits the
severity of the ischemia/reperfusion injury. Thus, after IP, the extent
of the area of a subsequent infarction is reduced by 30–80% versus
matched controls with matched risk areas. Preconditioning also
reduces ischemia/reperfusion arrhythmias and may reduce contrac-
tile dysfunction. At ﬁrst, preconditioning protection lasts a few hours
(2–3 h) immediately after the preconditioning maneuvers. This is the
so-called early classical preconditioning or ﬁrst window of protec-
tion, which is followed by a period without protection lasting about
12–24 h. Then, the protection reappears and lasts 24–72 h in the so-
called second window of protection (late preconditioning). Precon-
ditioning can also be obtained by inducing an ischemia on distant
organs (remote preconditioning) or by pharmacological treatment
before the index ischemia (pharmacological preconditioning) [for
reviews see 1–12,91].
Cardioprotection by ischemic preconditioning is triggered by
autacoids such as adenosine, bradykinin, opioids and platelet
activating factor, produced as a response to the cycles of brief
ischemia/reperfusion [for reviews see 1–12,91]. Their receptors
couple to signal transduction pathways that ultimately inhibit the
formation of mPTP during the reperfusion phase following the
infarcting ischemia (Fig. 2) [92–96]. In fact, the opening of mPTP
completely disrupts mitochondrial function and invariably leads to
cell death by either necrosis or apoptosis. It is likely that a large
number of cells are killed by this mechanism during reperfusion [73–
76,92,94–97]. In fact, infarcts in preconditioned hearts are smaller
than the size of those in non-preconditioned hearts which went an
identical ischemic insult. A similar, but not identical, mechanism
operates in postconditioned hearts (see below).
Cardioprotection by preconditioning requires a complex signaling
cascade, which includes the opening of mitochondrial ATP-sensitive
potassium channels (mitoKATP) [98–105]. In fact, diazoxide, a mitoK-
ATP opener, pharmacologically preconditions the heart [98,100].
Intriguingly the diazoxide-induced preconditioning can be completely
blocked when the drug is administered with a free radical scavenger,
such as N-acetyl-cysteine (NAC) or mercaptopropionyl glycine (MPG).
It is remarkable that these antioxidant compounds given during
preconditioning maneuvers also prevent the protective effects of
ischemic preconditioning. These results [98,100] conﬁrmed that redox
signaling is involved in cardioprotection by preconditioning.
6. Role of free radicals in preconditioning
Redox signaling in preconditioning is still not completely under-
stood, but it is widely accepted that transient, low concentrations of
Fig. 2. Schematic representation of ischemic preconditioning pathway. This scheme shows the different components of the cardioprotective pathway activated prior ischemia and at
the time of myocardial reperfusion by ischemic preconditioning. The two phases are schematically separated by vertical dashed lines. Prior to ischemia, many of the signaling
pathway converge on PKC, which may represent the memory of the preconditioning. During the reperfusion, pathways converge on mPTP which are considered the end effector of
preconditioning cardioprotection. A ROS signaling is considered in the two phases. Adenosine pathway acts via GPCR, but does not require ROS to activate PKC. More details are
provided in the text. Acronyms are as in the text.
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NO·, HNO, ONOO−) and ROS (i.e. O2− and H2O2) may be included
among the triggers of preconditioning, and it is likely that they
collaborate in inducing cardioprotection.
Even in 1988 Murry et al. [106] had linked ROS signaling to IP. They
reported in a preliminary study that the i.v. administration of the free
radical scavengers SOD and catalase had prevented preconditioning
with ischemia in many but not all dog hearts. These data suggested
that free radicals exerted a protective rather then deleterious effect in
ischemia/reperfusion scenario. Among the ﬁrst studies to show that
exogenous and endogenous free radicals are involved in the
myocardial protection by preconditioning were the studies by Baines
et al. [107] and Tritto et al. [60]. Subsequently, Vanden Hoek et al. [48]
demonstrated a ROS mechanism for “paradoxical” cardiomyocyte-
protectionwith oxidants, and increased cell death due to antioxidants.
They reported a loss of preconditioning protection and increased celldeath when the antioxidant MPG was delivered only during the
preconditioning period (then washed out prior to ischemia/reperfu-
sion). Moreover, they reported that hydrogen peroxide (15 μM) alone
given in lieu of hypoxic preconditioning for 10-min resulted in
protection against cell death.
In situ, the source of ROS during ischemic preconditioning appears
to be the mitochondria. In rabbit myocytes it has been demonstrated
that maneuvers which cause potassium ions to enter mitochondria
can cause ROS production. This type of mitoKATP-dependent ROS
production can be abrogated if the electron transport chain is blocked
by myxothiazol [88]. Yet, blocking mitochondrial MAO (monoamine
oxidase) abrogates cardioprotection by preconditioning (Di Lisa F,
unpublished observations). Recently, it has been reported that
isolated mitochondria can be made resistant to mPTP opening by
pretreatment with mitoKATP openers or potassium ionophores. This
protection is both protein kinase C (PKC)- and ROS-dependent,
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activation, resideswithin themitochondria [97,108]. In fact, Costa et al.
[108] suggested that protein kinase G (PKG) may phosphorylate an
unknown target at the mitochondrial outer membrane that would
lead to activation of a PKCɛ pool within the intermembrane space.
These authors also reported that PKG inhibits mPTP opening through a
mechanism involving activation of two mitochondrial pools of PKCɛ,
PKCɛ1 and PKCɛ2 [97]. The former will open mitoKATP, leading to a
modest increase in matrix H2O2. H2O2 would promote further PKCɛ1
activation, and activating PKCɛ2 would inhibit mPTP formation. It
seems that ROS released in response to mitoKATP opening can limit
injury via activation of a number of other kinases (e.g. p38-MAPK, JNK,
TK and ERK 1/2) and can act on connexin-43 [3,4,7,8,75,85].
In cardiomyocytes connexin-43 is also expressed in the inner
membrane of mitochondria [109–111]. Loss of mitochondrial con-
nexin-43 decreases ROS formation by diazoxide, leading to a loss of
pharmacological preconditioning-induced protection [110]. There-
fore, PKG, mitochondrial PKCɛ1 and 2, mitoKATP opening, connexin-
43, ROS generation, and inhibition of mPTP formation are connected
in a protective signaling pathway located inside the mitochondria.
However, this seems to be in contrast with the ﬁnding that NADPH
oxidase plays a pivotal role in ischemic preconditioning and that
NADPH oxidase-deﬁcient mice cannot be preconditioned [112]. It
cannot be excluded that cooperation exists between different
sources of ROS in preconditioning. Nevertheless, the cooperation
between different sources of ROS in triggering preconditioning is not
universally accepted, and little agreement exists among scientists
about the phase (ischemia or reperfusion) and the nature of ROS
involved in preconditioning triggering. The role of mitochondria
seems universally accepted, but the source within the mitochondria
is not clear. It has been suggested that ROS signaling occurs during
the occlusion phases of preconditioning stimulus. Studies have
demonstrated that superoxide and hydrogen peroxide [44–46]
production begins very early during preconditioning ischemia/
anoxia and ceases with the reintroduction of oxygen. Carmody and
Cotter [47] and Vanden Hoek et al. [48] proposed that ischemia-
generated oxidants from mitochondria are the source of ROS that
trigger preconditioning.
It has been suggested that MPG is a cell-permeant ROS scavenger
that removes hydroxyl radical and peroxynitrite very effectively and
blocks the protective effects of preconditioning e.g. [97–101]. Based on
these considerations, the group of Downey [113] used MPG to test
whether the ROS that triggers protection are produced during the
ischemic or the reperfusion phases of the preconditioning maneuvers.
These authors concluded that protective redox signaling occurs when
oxygen is reintroduced following the brief preconditioning coronary
occlusion. In fact, when MPG was infused immediately before
preconditioning and it was present in the myocardium during the
brief coronary occlusion, but not during the subsequent reperfusion,
preconditioning was still effective. However, when MPG was infused
during the reperfusion phase of the preconditioning maneuver,
protection was completely blocked. These data are in agreement
with the fact that an occlusion followed by reperfusion is required to
precondition the heart and with the observation that reperfusing the
heart with hypoxic perfusate during preconditioning maneuvers
increases the size of a subsequent infarction [113].
The putative target of ROS in preconditioning-induced redox
signaling is the PKC (possibly PKCɛ2); in fact hearts can be
preconditioned by simply infusing free radicals into the coronary
arteries and that protection can be blocked by a PKC antagonist [60].
Recently, it has been reported that ROS can activate PKC in vitro by
reacting with thiol groups associated with the zinc ﬁnger region of the
molecule [114]. PKC is known to act (either directly or indirectly) on
several proteins that are associated with the membranes of the
mitochondria, including the mPTP, mitoKATP channel, BAX/BAD and
Bcl-2 [3–8,76,97,108].In summary, themain idea of the preconditioning paradigm (Fig. 2)
is that during the ischemic phase autacoids are released, activate their
receptors, and lead to the opening of mitoKATP via a NO·-mediated
signaling;while during reperfusionphase the reintroduction of oxygen
leads to ROS formation by mitochondria. Kinases such as PI3K, PKB
(Akt), PKG and PKC are also involved either in the trigger (prior to
index ischemia) ormediator (at reperfusion) phase. Therefore, in early
preconditioning, signaling pathways converge again on the mitochon-
dria to produce cardioprotection [6,28,76,94–105,107–112,115–118].
After we had shown that ROS played a pivotal role in
postconditioning signaling [86, comments on 119] (see below),
studies by different groups reported that ROS produced during the
initial phase of reperfusion which followed a long-lasting infarcting
ischemia (index ischemia) were necessary for a preconditioned heart
to be effectively protected. A ROS scavenger added in the perfusate at
the end of an infarcting ischemia blocks cardioprotection in hearts
that have been previously preconditioned [120,121]. Nevertheless,
cardioprotection by a direct PKC activator given at reperfusion is
unaffected by the ROS scavenger MPG. These observations are
consistent with the idea that during the reperfusion phase a new
protective signaling is required. This includes the activation of several
kinases, which are called reperfusion injury salvage kinases (RISK)
[3,4,8,75,93,95,120,121–123]. Therefore, the paradigm is that the
production of autacoids during infarcting ischemia and the re-
population of autacoid receptors during the reperfusion phase may
lead to the activation of RISK, the opening of mitoKATP via a NO·-
mediated signaling, and again to ROS formation by mitochondria,
which play an important signaling role in the reperfusion phase
(Fig. 2). Thus, protective redox signaling take places during the early
reperfusion phase. It is likely that this signaling occurs before the
massive ROS burst, which characterizes reperfusion injury.
In brief, ROS signaling during preconditioning maneuvers and
during the early reperfusion phase, which follows an index ischemia,
makes the heart resistant to reperfusion injury. The reperfusion
injury in a control/naive heart includes massive ROS production and
mPTP opening. In a preconditioned heart whether this massive
production does not occur or is less injurious is not very clear. Since
“ROS-induced ROS release” requires mPTP opening [41], it is more
likely that in protected hearts (where mPTP opening does not occur)
a massive ROS production does not take place. So that in protect
hearts RISK, mitoKATP, and ROS signaling, in concert, lead to
protection including mPTP closure. In other words, when mPTP
formation is avoided ROS production is reduced because ROS-
induced ROS release does not occur. However, an improvement of
antioxidant properties, including increased NO· synthesis, plays also
a pivotal role [14,19,23,31,44,54,70].
Regarding nitric oxide and RNS, it has been demonstrated that they
can act both as a trigger and as a mediator of the preconditioning
response in a variety of species. NO· can be produced during
preconditioning maneuvers and during the reperfusion phase as
well. The role of endogenous NO· in classic ischemic preconditioning
was controversial. In the early 1990 s NO· donors were believed to
decrease myocardial necrosis and reperfusion-induced endothelial
dysfunction [125]. Similar observations were made concomitantly in
the gut mesentery [126]. Protective effects of NO· donors were also
later demonstrated in brain and liver ischemia [18,127]. Cohen and
Downey's group suggested that exogenously administered NO· could
trigger the preconditioned state through a free radical-mediated
process not shared by endogenous NO·. Very recently these authors
questioned whether their observation was due to a bias in the
experimental model. These authors are now of the opinion that
endogenous NO· participates in triggering in vivo preconditioning
[128]. The ambiguity (exogenous versus endogenous) was in part a
result of the extrapolation of in vivo pathogenic conditions from in
vitro toxicological experiments. A retrospective analysis of 92 studies
evaluating the modulatory effects of NO· on the severity of ischemia/
Fig. 3. Schematic representation of ischemic postconditioning protocol. Ischemic
postconditioning (PostC) limits the severity of the ischemia/reperfusion injury.
Infarct area is reduced by 20–70% versus matched controls with matched risk areas.
PostC also reduces reperfusion arrhythmias and may reduce post-ischemic endothe-
lial dysfunction.
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beneﬁcial effects of exogenous or endogenous NO· in the majority
(67%) of the contributions [1]. In the ischemic heart, NO· can provide
protection through several mechanisms including inhibition of
platelet aggregation [129] and neutrophil activity and adhesion
[130] in a cGMP-dependent manner. The effect of NO·, either
through exposure to NO· donors or L-arginine, is proposed to be
dependent on the stage of ischemia/reperfusion, with maximal
protection against myocardial injury occurring with drug adminis-
tered either immediately before or during the onset of reperfusion
[1,2,77]. Furthermore, infarct size and post-ischemic myocardial
functional recovery in endothelial NOS knockout mice are worse
than in wild-type [131–134]. In addition, endothelial NOS-deﬁcient
hearts showa transient (about 1 h) increase in contractility in the early
periods of reperfusion. In these hearts, bolus administration of NO·
donors before the index ischemia prevents the hypercontractile
response during early reperfusion while signiﬁcantly reducing
myocardial damage [133]. While prevention of hypercontractility
may depend on the effect of high concentration of NO and cGMP in
myocardium, protection is likely to be due to the antioxidant
properties of NO·, which not only safeguards against chemical insult
from massive ROS (or RNS) [14,19,23,70] but also exerts other
beneﬁcial effects. For example, NO· is a powerful vasodilator and
may improve blood ﬂow during reperfusion [9–11,18,134–136]. NO·
also inhibits inositol-1,4,5-trisphosphate signaling, thereby reducing
calcium overload [137], andmediates PKC translocation at reperfusion,
thus protecting contractile function in isolated rat heart [138].
Although the reaction of NO· with O2 produces ONOO− [67,69],
which is considered to be cytotoxic [54,139], NO· donors confer
vascular protection against exogenously applied ONOO− [43] via
secondary reactions [14–16]. Nitric oxide also modulates myocardial
oxygen consumption in the normal and failing heart [36,140,141].
The role of NO· is now fully recognized in preconditioning, and its
effects are well-deﬁned, particularly in the second window of
protection [for review see 1–12]. Intriguingly, in a comparative
study of the activity of Angeli's salt, an HNO donor, with that of the
pure NO· donor diethylamine/NO· (DEA/NO·), we demonstrated
that equimolar (1 μM) amount of HNO appeared to be more effective
than NO· as a preconditioning agent [142]. In fact, in isolated rat
hearts post-ischemic contractility was similarly improved with
ischemic preconditioning or pre-exposure to Angeli's salt, compared
with control or DEA/NO pre-treated hearts. Similar results were
obtained regarding the limitation of infarct size and lactate dehy-
drogenase release. Moreover, the preconditioning features of Angeli's
salt appeared to be speciﬁc to HNO signaling because the HNO
scavenger NAC (4 mM) completely reversed the beneﬁcial effects of
Angeli's salt. These data suggest that reactive nitrogen oxide species
are not only necessary but also sufﬁcient in triggering myocardial
protection against reperfusion through species-dependent, pro-
oxidative, and/or nitrosative stress-related mechanisms. In fact, the
rapid reaction of thiols with HNO produces RSNHOH species [21,31].
This intermediate can then react with a reduced thiol to form an
oxidized disulﬁde. Therefore, biomolecules that can be oxidized by
ONOO− may also be converted to the same end-products following
exposure to Angeli's salt through either direct binding of HNO or
indirectly via its oxidized intermediate. The enhanced, thiol-depen-
dent protection induced by HNO compared to equimolar NO·
suggests a mechanism involving either an oxidative alteration or the
involvement of critical thiols or metals [32,142]. Therefore, it is not
surprising that using NAC a complete inhibition of the protective effect
exerted by Angeli's salt can be obtained without signiﬁcant alterations
to any other of the studied parameters. The effect of Angeli's salt on
thiols is in line with the fact that free radicals can activate PKC in vitro
by reacting with its thiol groups [114]; thiols are also oxidized by
ONOO− which has been indicated as preconditioning inducer [113].
Whether HNO per se or its oxidative product is responsible forpreconditioning remains to be elucidated as does whether the isolated
heart model can be extrapolated to in vivo conditions and to a more
sustained response (i.e., late preconditioning).
7. Deﬁnition of postconditioning
Although it has been shown that preconditioning can make
ischemic myocardium resistant to ischemia/reperfusion injury, the
need for a pretreatment could limit its clinical application. During late
1980s and 1990s researchers intensively investigated whether or not
pharmacologically modiﬁed reperfusates could reduce reperfusion
injury. Moreover, several studies examined whether myocardial
damage by ischemia/reperfusion could be limited if reperfusion was
initiated in a gentle (low pressure)manner as opposed to standard full
ﬂow (high pressure) [143–150]. It soon became clear that the window
of opportunity during reperfusion is very limited. The efﬁcacy of these
mechanical or pharmacological interventions initiated later than 5–
10 min after the beginning of reperfusion resulted in markedly limited
addition of cardioprotection to reperfusion per se.
These observations together with the data on preconditioning
prompted the Vinten-Johansen group [151] to study cardioprotection
with stuttering reperfusion immediately after an infarcting ischemia
(Fig. 3). This procedure was called ischemic postconditioning
(PostC). PostC can be deﬁned as intermittent interruption of
coronary ﬂow in the very early phase of a reperfusion, which
leads to cardioprotection. Vinten-Johansen group [151] was the ﬁrst
to describe a role for PostC against infarct size. In such a study the
PostC protocol was 30 s of reperfusion followed by 30 s of coronary
occlusion, which were repeated for three cycles at the very onset of
reperfusion. Then, also for PostC, it became clear that the window of
opportunity is very limited. PostC initiated later than 1–3 min after
the beginning of reperfusion resulted ineffective in inducing
cardioprotection [152–156].
Depending on the species, models and other factors, PostC reduces
infarct size by ∼20–70% versus matched controls with matched risk
areas [3,4,12,92,155,156]. Unlike preconditioning, PostC does not
protect against stunning [157,158]. There is an emerging agreement
across multiple models and species that PostC may reduce apoptosis,
necrosis, endothelial dysfunction and endothelial activation, thus
leading to a reduced endothelia/leukocyte interaction and to a
reduced ROS inﬂammatory formation. A reduced incidence of
reperfusion arrhythmias has been also observed [159–161]. It is
noteworthy that already by 1994 Grech and Ramsdale [162] had
reported that coronary artery re-canalization by percutaneous
transluminal coronary angioplasty (PTCA) induced an idioventricular
rhythm, which was interrupted several times by the re-inﬂation of the
balloon and thus restoring sinus rhythm.
It is now widely accepted that PostC has interrelated passive and
active components in its underlying cellular protective mechanisms
[3,4,12,91,155,156]. During the PostC maneuvers, the washout of
intracoronary release of adenosine is signiﬁcantly delayed so that it
can take part in protection [152]. An involvement of kinins and opiods
in the early reperfusion phase has also been suggested [91,163–165].
These autacoids acting on their cardiac sarcolemmal receptors can
triggers the signaling cascade of PostC [4,12,91,155,156]. In fact,
postconditioning involves signal transduction pathways, which are
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autacoids can trigger a complex protective signaling pathway (Fig. 4)
including RISK signaling [4,12,91,155,156,163–170]. The exact subtypes
of adenosine, opioids, and bradykinin receptors involved in triggering
PostC are still a matter of controversy. With regard to the role of
adenosine in a ischemia/reperfusion scenario a plethora of complex
and conﬂicting results is reported. These conﬂicting results are also
due to the presence of different adenosine receptors (A1, A2A, A2B, A3)
with different degrees of sensitivity during normoxia, ischemia, and
reperfusion [for reviews see 91,171,172]. Despite a general agreement
on the involvement of adenosine receptors in cardioprotection at
reperfusion, the exact timing and receptor subtype(s) that are
responsible for triggering PostC remain controversial [91,171,172].
The role of adenosine A2A receptors was recently conﬁrmed byFig. 4. Schematic representation of ischemic postconditioning pathway. This scheme shows t
the time of full reperfusion) postconditioning maneuvers. The two phases are schematical
signaling pathway converge on PKC, which may represent the memory of the postcondit
protective pathways converge onmPTP which are considered the end effector of postconditio
that adenosine pathway acts via GPCR, but does not require ROS signaling. More details areabrogation of PostC in mice lacking A2A [173]. However, another in
vivo rabbit study reported a blockade of PostC by an A2B receptor
antagonist, MRS1754, but not by A1 antagonist, DPCPX, nor A2A
receptor antagonist, 8-(13-chlorostyryl)-caffeine [153]. Yet, in an in
vivo rat model using the blockers of adenosine A1 (DPCPX), A2A
(ZM241385) or A3 (MRS1523) receptors at the onset of reperfusion,
Kin et al. [152] concluded that A2A and A3, but not A1 receptors are
important for PostC-induced cardioprotection. In contrast, in a recent
study Donato et al. [174] reported that the administration of the A1
blocker, DPCPX, abolished PostC-induced reduction of infarct size in
hearts subjected to global ischemia/reperfusion, regardless they were
isolated from normal or hypercholesterolemic rabbits. These data
were conﬁrmed by a recent study in which a complete loss of
PostC-induced cardioprotection was observed in A1-knockout micehe different components of the cardioprotective pathway activated during and after (at
ly separated by vertical dashed line. During postconditioning maneuvers many of the
ioning, at the same time the low pH prevent mPTP opening. During the reperfusion,
ning cardioprotection. A ROS signaling is considered during PostC maneuvers. It is likely
provided in the text. Acronyms are as in the text.
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are essential for cardioprotection at reperfusion. In our recent
publication [167], we conﬁrmed the involvement of adenosine
receptors in PostC in isolated rat hearts. In fact, a three min blockade
of all adenosine receptors with 8-SPT prevented PostC protection.
However, neither adenosine infusion for three min (i.e. without
intermittence) nor intermittent-adenosine application in the early
reperfusion phase triggered PostC protection. We suggested that
adenosine coupling with receptors is necessary, but not enough, for
postconditioning protection. It is likely that other concomitant
events (i.e. intermittent bradykinin B2 and/or opioid receptor
activation with ROS production) are necessary to induce postcondi-
tioning protection. This hypothesis of concomitant ROS release is
also supported by the observations that ROS signaling is mandatory
in PostC and that adenosine (possible via A2B receptors) may induce
preconditioning without ROS production [99]. It is, thus, possible,
that adenosine per se does not trigger protection because it does not
trigger ROS signaling; yet adenosine receptor occupation may be
necessary to support PKC activation by PostC (see below).
If the role of adenosine is controversial and unclear, there is,
instead, a unanimous agreement on the crucial importance of
bradykinin B2 receptors in myocardial protection, such as ischemic
and pharmacological preconditioning [12,91,99,104,163,164,175–177].
We were the ﬁrst to show that pharmacological inhibition of B2
receptors by administration of HOE140 orWIN64338 blocks the infarct
size reduction afforded by PostC or intermittent bradykinin infusion at
the onset of reperfusion [163]. The notion that bradykinin B2 receptors
are indispensable in PostC, is further supported by a recent study in
which the infarct-limiting effect of PostC observed in wild-type mice
was completely lost in B2-knockoutmice [175]. This study also showed
that genetic deﬁciency of bradykinin B2 receptors did not signiﬁcantly
modify myocardial tolerance to ischemia/reperfusion injury, as
indicated by the similar infarct size observed in wild-type and
knockout mice in the absence of PostC. Similar results were observed
after in vivo ischemia/reperfusion in B2-knockout mice [176,177].
These results further suggest that the intact presence of bradykinin B2
receptors at the early onset of reperfusion is critical for transmitting
the cell survival signals of PostC. Moreover, bradykinin-induced
preconditioning requires ROS production [99,104], which is also
crucial for PostC-induced cardioprotection [86,119,163].
8. Role of free radicals in postconditioning
The importance of a reduced endothelial activation, neutrophil
adherence and consequently redox-sensible mechanisms in PostC
was shown by Zhao et al. [151]. PostC decreases the expression of P-
selectin, an adhesion molecule, on the surface of endothelial cells,
with both a reduction in neutrophil adhesion on the postconditioned
coronary artery endothelium and a reduced accumulation of
neutrophils in the area at risk [151]. A reduction in superoxide
anion generation in the perivascular area has also been observed in
the proximity of risk area of postconditioned hearts [178–180].
Whether the reduced neutrophil accumulation, the subsequent ROS
production and the pro-inﬂammatory response is a cause or an effect
of necrosis, apoptosis and vascular injury was not clear. It now seems
clear that the reduced neutrophil accumulation and its reduced ROS
production is an effect of PostC protection. As a matter of fact, PostC
exerts a marked cardioprotection in leukocyte-free models (isolated
buffer perfused hearts and isolated cardiomyocytes) [e.g.
[86,152,158,163,167,169,181,182].
8.1. Cardioprotection by postconditioning is redox-sensitive
The above ﬁndings of a reduced ROS production in PostC
[151,178–180] are in line with the idea that massive ROS production
is implicated in the sequel of myocardial reperfusion injury. Asmentioned above, it has already been established that precondition-
ing triggering, i.e. the period that precedes the index/infarcting
ischemia, is redox-sensitive (i.e. requires ROS signaling). This was
demonstrated by both avoiding preconditioning with ROS scavengers
and inducing preconditioning with ROS generators given before the
index ischemia [e.g. 52,60,98–100,103–107,110]. Also, many G-
protein-coupled receptor (GPCR) activators, including acetylcholine,
bradykinin, opioids and phenylephrine, trigger preconditioning-
like protection via a mitoKATP-ROS-dependent mechanism
[e.g. 52,60,98–100,103–107,110]. All these studies supported the
paradigm that ROS may be protective in pre-ischemic phase, but
are deleterious in the post-ischemic phase. Thus the main idea was
that ROS play an essential, though double-edged, role in cardiopro-
tection: they may participate in reperfusion injury or may play a role
as signaling elements of protection in pre-ischemic phase [e.g. 4–11].
Intriguingly, and in contrast with the above-described theory of
ROS as an obligatory part of reperfusion-induced damage, some
studies in the 1960–70s [183–187] and in more recent years [188,189]
suggested the possibility that some ROS species at low concentrations
could protect ischemic hearts. Based on this suggestion we were the
ﬁrst to consider that ROS could also be included among the triggers of
PostC [86,119]. Moreover, as reported above, very recently it has been
shown that redox signaling is also required at the time of myocardial
reperfusion (i.e. after infarcting ischemia) to mediate the cardiopro-
tection elicited by ischemic preconditioning [120,121].
Therefore, the role of free radicals in reperfusion may be
reconsidered as they are not only deleterious. This fact may also
help in understanding the variability in the results of studies aimed at
proving a role of ROS in reperfusion injury [83–85]. In fact, we and
other authors have shown that ROS scavengers such as NAC and MPG
given during the PostC maneuvers prevented the protective effects
[86,119,163,165]. It is possible that the low pH during the PostC cycles
prevents mPTP opening, while the intermittent oxygen bursts
produced during PostC maneuvers allow mitochondria to make
enough ROS in a moment in which other enzymes, able to produce
massive quantity of ROS, are not yet re-activated. Then mitochondrial
ROS may activate PKC and put the heart into a protected state (Fig. 4).
The importance of the role of acidosis in triggering PostC protection
has been conﬁrmed by two independent laboratories [74,95,190].
Recently, it has been reported that redox signaling and a low pH at the
time of myocardial reperfusion are also required to mediate the
cardioprotection triggered by ischemic preconditioning [120].
From the above reported mechanisms of PostC, it appears that
ischemic PostC is a cardioprotective phenomenon that requires the
intervention of redox signaling to be protective. However, we have been
unable to reproduce cardioprotection with ROS generation by purine/
xanthine oxidase given at reperfusion [163]. Since ROS scavengers (NAC
andMPG), given at the beginning of reperfusion, abolished both IP- and
PostC-induced protection [86,119–121,163,165], it is likely that the type,
the concentration, and/or the compartmentalization of ROS may play a
pivotal role in triggering protection at reperfusion time. Our present
studies aim to clarify this issue. Recent preliminary reports by the
Ferdinandy Group [191] as well as by our group [192] point towards an
important role for ONOO−. These observations stress the importance of
NO· biochemistry in redox conditions.
As mentioned above, the mechanism by which NO· protects
myocardium includes the activation of guanylate-cyclase [1–12,31,36].
As an inducer of the protection, NO· may also directly open the
mitoKATP channels [102,193]. Therefore, NO· acting on mitochondria
may play a relevant role in protection both through activation of these
channels and viamodulation of the respiratory chain; bothmechanisms
favor ROS signaling, which can lead to protection [31,88,103–111]. A
relevant role ofNO·mayalsobeattributed to the endothelial protection
brought about by this molecule [10,11,38,125,132,136,194] as well as to
its role as an antioxidant under certain conditions [9,14,19,20,195].
Moreover, as discussed above, one of the pivotal steps in
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thiol groups associatedwith the zincﬁnger region of themolecule [114].
The involvement of ONOO− in this reaction/activation has beenwidely
considered in late preconditioning [for reviews see 2,7,10] but not
adequately considered in postconditioning yet.
Also the one-electron-reduction product of NO·, HNO (nitrosyl
hydride), has been scarcely studied in an ischemia/reperfusion
scenario. As mentioned above, we have shown that low doses of
Angeli's salt, a donor of HNO, induce early/classical preconditioning
against myocardial damages, which were more potent than the
protective effects induced by equimolar concentration DEA/NO [142],
yet the HNO donor seems deleterious in reperfusion [196]. However,
there is evidence that NO· may also be involved in the cardioprotec-
tion by ischemic PostC. When the NOS inhibitor Nω-nitro-L-arginine
methyl esther (L-NAME) was given 5 min before the beginning of
reperfusion to in situ rabbit hearts, the infarct-limiting effect was
abolished [154]. We have shown that NO· participates in rat heart
PostC, but NOS inhibitors given for the entire period of reperfusion
only blunted, but did not suppress, the protective effect of PostC [166].
Paradoxically, the same inhibitor, given only during PostC maneuvers
suppressed the protective effects [163]. At present we have not yet
found an explanation for this apparent paradox. In our previous study,
we argued that NO· might be produced in postconditioned heart by
both NOS and non-enzymatic mechanisms. Nitric oxide can then
activate the guanylyl cyclase to produce cGMP and/or to react with O2
− to form ONOO−, which mediate the protection [166] (also see
below). The infusion of a NOS inhibitor only during PostC maneuvers
[163]may alter the equilibrium between ROS and NO· thus leading to
the production of the wrong kind of radicals, which do not trigger the
protective pathway. It can be argued that in the absence of this
protection the stronger limitation of NO· production by NOS
inhibitors may be protective during reperfusion. In fact, it has been
demonstrated that NOS inhibitors can attenuate ischemia/reperfusion
damage [1,65,77]. The different doses of NOS inhibitors applied and
the different basal levels of NO· endogenously produced may explain
these disparities. Recently, a signiﬁcant role for nitrite in ischemia/
reperfusion injury has been suggested. Nitrite is an oxidation product
of NO· which was considered inert. However, mice treated with
sodium nitrite at the end of myocardial ischemia showed marked
reduction in infarct size compared with nitrate-treated mouse
hearts, an effect abolished by the NO· scavenger, 2-phenyl-
4,4,5,5,-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) [197]. These
authors proposed that the post-ischemic myocardial environment
might allow for the acidic reduction of nitrite to NO·. Alternatively,
xanthine oxidoreductase may catalyze such a transformation of
nitrite during hypoxic/acidotic conditions [198]. The beneﬁcial and
deleterious effects of NO· and nitrite in pathophysiological condi-
tions and the contradictory results about the effects of NO· during
reperfusion have been reviewed by several authors [1,9,10,65,77,199].
In summary, it appears that the trigger pathway for PostC involves
the following sequence of events: occupation of surface receptors (i.e.
adenosine, bradykinin and opioid receptors), activation of NOS and
non-enzymatic processes to produce NO·, activation of cGMP-
dependent kinase (PKG), opening of mitoKATP, production of ROS
and possibly synthesis of ONOO−, and ﬁnally activation of PKC and
MAPKs as well as inhibition of GSK3β, which put the heart into a
protected state [3–7,76,93–95,123]. The protected state includes a
central role of the prevention of mPTP opening by acidosis in the early
phase of reperfusion and by the aforementioned mechanisms (RISK)
(Fig. 4). We consider ROS among the triggers, as they are necessary
during PostC maneuvers. Nevertheless, PostC activated the RISK
pathway, with increased expression of the phosphorylated form of
eNOS (p-eNOS) as one of the results [3–7]. It is, thus, likely that after
NOS activation cGMP is produced and PKG activated, then mitoKATP
channels are opened and ROS may be produced by mitochondria.
Therefore cGMP, PKG, mitoKATP and possibly ROS may be consideredas mediators of PostC protection, which are likely to converge on PKC
activation. As said, this activation may depend on thiol reaction.
Hence, it is likely that acidosis transiently prevents mPTP opening
until PKC is activated and GSK3β inhibited to put the heart into a
protected state via long-term mPTP closure. The role of RISK and
GSK3β in PostC protection has recently been questioned [200,201]
and a role for JAK/STAT pathway has been proposed [202,203]. We
suggested an important role for cyclooxygenase (COX) and prostacy-
clin in PostC [164]. Thus the role of RISK, GSK3β, COX and JAK/STAT
pathways in PostC need to be studied further. This also suggests a
redundancy of mechanisms that are not mutually excluding each
other, but include an involvement of ROS signaling.
8.2. In conclusion
Although the mechanisms of cardioprotection by pre and post-
conditioning are similar, important differences go beyond the simple
intervention of mechanisms before and/or after ischemia. It is likely
that the ROS signaling involved in pre- and post-ischemic phases are
not the same. Since exogenous ROS are able to induce pre but not
postconditioning, it is also likely that compartmentalization plays a
pivotal role in the latter case. In particular, the concomitance of
acidosis, NO· formation, mPTP inhibition and ROS generation seems
mandatory in PostC.
From a clinical point of view, situations in which the ischemic event
can be predicted are limited, so that the practical application of
preconditioning maneuvers is very low. Yet, postconditioning can be
applied in different clinical situations (e.g. percutaneous coronary
intervention, coronary artery bypass grafting, and cardiac surgery)
when reperfusion is initiated. Initial clinical studies are in agreement
with the success and extent to which PostC reduces infarct size and
myocardial injury, even in the presence of other pathological conditions
[124,204–207].
The possibility to induce PostC pharmacologically would be of
paramount importance. Indeed, in the literature, several studies are
focused on the effects of cardioprotective drugs administered either
before or during the index ischemia or at the onset of reperfusion.
Some of the drugs leading tomyocardial salvage if given at reperfusion
include PKC activators, adenosine, bradykinin, erythropoietin, nitric
oxide donors and opiods. However, the strategy of adding reperfusion
therapeutics to save myocardium has not yet been adopted into
clinical practice. We opened a new strategy mimicking PostC with
very brief intermittent periods of drug infusion in the early
reperfusion [163,164,167]. Understanding the PostC mechanisms
may improve the protective results of drug administration that is
otherwise limited by systemic hemodynamic side effects or other
harmful or unwanted side effects of the agents. The beneﬁcial role of
free radicals even in early reperfusion, as demonstrated by pre and
postconditioning studies, open the future to mimetic agents that can
induce cardioprotection without interfering with early redox condi-
tions (ROS signaling) triggered by protective maneuvers.
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